Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative therapeutic solutions for the treatment of obstructive sleep apnea (OSA). Their primary product features a novel implantable neurostimulator designed to improve airway muscle function during sleep, thereby reducing the frequency of breathing disruptions caused by OSA. Nyxoah's approach offers a minimally invasive alternative to traditional continuous positive airway pressure (CPAP) therapy, aimed at enhancing patient comfort and compliance. The company is dedicated to advancing the understanding and treatment of sleep disorders, striving to improve the quality of life for patients worldwide. Read More
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
